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2INTRODUCTION
Graft-versus-host disease (GVHD) remains the principal
complication following allogeneic hematopoietic stem cell
transplantation (HSCT) as a treatment for several hemato-
logic disorders, including all forms of leukemia [1]. The
donor T cells mediating GVHD can be directed against
HLA or minor histocompatibility antigen (miHA) disparities
expressed by host tissues [2-5]. Although the approach of
depleting all T cells from the donor stem cell inoculum,
derived from either bone marrow or mobilized peripheral
blood populations, has been successful in decreasing the inci-
dence and severity of GVHD, this approach has also led to
increased development of graft failure, leukemic relapse, and
opportunistic infections [6]. Identification of the specific
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ABSTRACT
Lethal graft-versus-host disease (GVHD) can be induced after hematopoietic stem cell transplantation between major
histocompatibility complex–matched murine strains expressing multiple minor histocompatibility antigen (miHA)
differences. In the C57BL/6By (B6) → C.B10-H2b/LiMcdJ (BALB.B) irradiation model, both CD4+ and CD8+ donor
T cells can mediate lethal GVHD, whereas in the B6 → CXB-2/By (CXBE) model, in which the recipient expresses a
subset of BALB.B miHA, only the CD8+ T cells are lethal. Phenotypic analysis of CD4+ T cells collected from the tho-
racic duct lymphocyte pool of recipient mice had indicated expansion of the donor T-cell receptor V6-9 families in
BALB.B recipients, and only V7 and V9 populations in CXBE mice. CDR3-size spectratyping, used to further ana-
lyze these responses, revealed overlapping oligoclonal expansion of V4, V6-10, and V12-14 families in both
BALB.B and CXBE recipients injected with host-presensitized B6 T cells. In addition, the B6 → BALB.B CD4+ T-cell
response appeared to involve the recognition of unique BALB.B-specific miHA, indicated by additional skewing of
V2 and V11 families. On the other hand, the B6 → CXBE strain combination exhibited unique skewing of the V16
and V18 families. Immunohistochemical staining of lingual epithelial sections from BALB.B recipients of naive B6
CD4+ T cells correlated with the involvement of several of the spectratype-skewed V families in GVHD lesions. Fur-
thermore, magnetic cell separation techniques were used to positively select the spectratype-skewed V families
from the donor B6 CD4+ T cells; the former were found to have significant GVHD potential upon transplantation into
lethally irradiated BALB.B recipients. In contrast, mice that received transplants from the unskewed V families all
survived with minimal symptoms of GVHD. Taken together, these results demonstrate that the expansion of particu-
lar V families, as identified by spectratype analysis, correlates with the induction and pathogenesis of lethal GVHD.
KEY WORDS
Graft-versus-host disease • Bone marrow transplantation • Minor histocompatibility antigens •
T-cell repertoire
Biology of Blood and Marrow Transplantation 7:2-13 (2001)
© 2001 American Society for Blood and Marrow Transplantation ASBMT
This research was supported by US Public Health Service Research Grants
HL55593 and CA40358.
CD4+ TCR V Repertoire in GVHD
3B B & M T
alloreactive T cells responsible for the induction of GVHD
could lead to their selective depletion, while allowing the
residual T cells to potentially support engraftment and/or
counteract the occurrence of leukemic relapse and infections.
Selective removal of GVHD-mediating donor T cells would
likewise be advantageous for delayed lymphocyte infusion
approaches, which are administered months after HSCT and
are currently being used to stave off leukemic relapse [7] or
targeted infections such as those of Epstein-Barr virus, which
has a high rate of inducing lymphomas [8].
MiHA play a particularly important role in the develop-
ment of GVHD following major histocompatibility complex
(MHC)-matched allogeneic HSCT [9-12]. Because individual
miHA can be presented by either MHC class I or II mole-
cules, both CD8+ and CD4+ T cells can participate in the
development of GVHD [13-15]. In most miHA-disparate
murine experimental models, CD8+ T cells have a clear etio-
logical association with lethal GVHD, and they can function
independently or depend on the cytokines provided by donor
CD4+ T cells [16,17]. On the other hand, in certain strain
combinations, CD4+ T cells alone have been capable of induc-
ing lethal GVHD directed to miHA, although the factors that
control these responses are not well understood [16-19].
To further investigate the complexity and diversity of the
miHA-specific CD4+ T-cell response in GVHD, we have
focused our attention on the B6 → BALB.B strain combina-
tion, in which lethal disease does develop [17]. Phenotypic
analysis of the T-cell receptor (TCR) V repertoire of CD4+
T cells collected in the thoracic duct lymphocyte (TDL)
pool of irradiated recipient mice during the initial develop-
ment of GVHD had suggested that there was a limited dom-
inant T-cell response to miHA [20]. The CD4+ T cells
exhibited notable expansions of the V6, -7, -8, and -9 fami-
lies as analyzed by ﬂow cytometry with V-speciﬁc mono-
clonal antibodies (MoAbs). By comparison, in the B6 →
CXBE recombinant inbred (RI) strain combination, which
expresses a subset of the BALB.B miHA, CD4+ T cells did not
cause lethal GVHD, and the phenotypic repertoire analysis
indicated expansions of the V7 and -9 families only. However,
despite these interesting ﬁndings, this initial study was lim-
ited by the lack of availability of MoAbs to detect all V fam-
ilies and the overall insensitivity of trying to detect signiﬁ-
cant shifts in TCR use in relatively small T-cell populations.
As recently found for the analysis of the CD8+ V repertoire
in these strain combinations, the response is likely to be
more complex than indicated by phenotypic analysis [21].
Polymerase chain reaction (PCR)-based TCR V
CDR3-size spectratyping is a highly sensitive means of
characterizing the repertoire of a T-cell response [22,23].
Skewing of the normal CDR3-size distribution within an
individual V family is indicated by selective increases in
band intensities and is suggestive of either clonal or oligo-
clonal T-cell response [24]. In the current study, we have
used this approach to further analyze the CD4+ T-cell anti-
miHA GVHD response in the B6 → BALB.B and B6 →
CXBE strain combinations, 5 days after transplantation of
host-presensitized B6 donor T cells. The results demon-
strated that the lethal CD4+ T cell-mediated GVHD
response in the B6 → BALB.B model involves a limited yet
heterogeneous repertoire directed to immunodominant
miHA expressed in the recipient target tissues. This reper-
toire has extensive overlap with that found in the nonlethal
B6 → CXBE model but also has some unique V family
specificity involvement that might contribute to the more
lethal nature of the response. Immunohistochemical stain-
ing of serial sections from lingual epithelium in the B6 →
BALB.B model revealed significant cellular infiltration of
several of the skewed V families in the GVHD epithelial
lesion. In support of these combined results, positively
selected donor B6 CD4+ T cells from spectratype-skewed
V families were transplanted into lethally irradiated
BALB.B recipients and resulted in the development of lethal
GVHD, whereas mice that received unskewed V families
all survived with minimal symptoms of GVHD.
MATERIALS AND METHODS
Mice
C.B10-H2b/LiMcdJ (BALB.B), CXB-2/By (CXBE), and
C57BL/6By (B6) mice, all of the H2b haplotype, were pur-
chased from the Jackson Laboratory (Bar Harbor, ME) or
raised in our breeding colony from breeder pairs provided by
the Jackson Laboratory. For all experiments, sex-matched
mice were used as donors and recipients between the ages of
7 and 16 weeks. Mice were kept in a pathogen-free environ-
ment in autoclaved microisolator cages and were provided
with acidiﬁed (pH 2.5) water and autoclaved food ad libitum.
Media
Phosphate-buffered saline (PBS) (BioWhittaker, Walk-
erville, MI) supplemented with 0.1% bovine serum albumin
(BSA) (Sigma, St. Louis, MO) was used for all in vitro manip-
ulations of lymphocytes. RPMI 1640 supplemented with
2 mmol/L L-glutamine, 50 U/mL penicillin, 50 µg strepto-
mycin (all from Mediatech, Herndon, VA), 10% fetal calf
serum (FCS) (Sigma), and 5 U/mL heparin sulfate (Schein
Pharmaceutical, Florham Park, NJ) was used for TDL collec-
tion. PBS supplemented with 1% BSA and 0.1% sodium
azide (fluorescence-activated cell sorting [FACS] medium)
was used for analysis of stained cells by ﬂow cytometry.
Irradiation
Recipient mice received a lethal dose of whole body
irradiation (8.5 Gy) from a Gammacell 137Ce source (Atomic
Energy of Canada, Kanata, ON, Canada) at a dose rate of
1.16 Gy/min.
Monoclonal Antibodies 
Ascites fluid for anti-Thy1.2 MoAb (J1j; rat immuno-
globulin [Ig]M [25]), anti-CD4 MoAb (GK1.5; rat IgG [26]),
and anti-CD8 MoAb (3.168; rat IgM [27]) were used for cell
preparations. Afﬁnity puriﬁed goat anti-mouse IgG (whole
molecule) antibody was purchased from Cappel-Organon
Teknika (West Chester, PA). Fluorescein isothiocyanate
(FITC)-conjugated anti-CD4 (clone RM4-5; #01064D),
anti-CD8 (clone 53-6.7; #01044D), puriﬁed and FITC-con-
jugated MoAbs speciﬁc for , V2, -3, -4, -6, -7, -8, -9, -10,
-11, -12, -13, and -14, and biotinylated MoAbs speciﬁc for
V5.1/5.2, 8.1/8.2/8.3, 9, and 13 were purchased from
PharMingen (San Diego, CA). Puriﬁed anti-CD3 MoAb was
purchased from Antigenix America (Franklin Square, NY).
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Preparation of Donor Cells
T cell–enriched donor cells were prepared from pooled
spleen and lymph node (LN) cell suspensions from naive B6
mice or those that were presensitized and then boosted with
either BALB.B or CXBE spleen cells (1.5  107 cells,
intraperitoneal [IP] injections, 2.5 weeks apart). The cells
were initially resuspended in Gey’s balanced salt solution
containing 0.7% NH4Cl to remove red blood cells and ﬁl-
tered through a cell strainer to remove dead cells. B cells
were removed by panning the cell suspension over goat anti-
mouse IgG–coated plastic petri dishes for 1 hour at 4°C.
The nonadherent (T cell–enriched) cells were harvested; the
population was 85% to 90% CD3+, as determined by ﬂow
cytometry. In some experiments, CD8+ T cells were
depleted by incubation with 3.168 MoAb (1:100 dilution of
ascites fluid) and guinea pig C (1:30 dilution) in 6 mL of
PBS plus 0.1% BSA at 37°C for 50 minutes. This cell popu-
lation was >95% CD4+. Anti-T-cell–depleted bone marrow
(ATBM) was prepared by ﬂushing cells from the femurs and
tibias of B6 donor mice with PBS plus 0.1% BSA, followed
by incubation with J1j MoAb (1:100 dilution) and guinea pig
C (1:30 dilution) for 50 minutes. Separation of V-skewed
CD4+ T cells was performed as previously described [21].
Brieﬂy, CD4+ T cells were incubated with a panel of FITC-
conjugated MoAbs specific for the skewed V families in
PBS for 30 minutes at 4°C. Cells were washed twice in PBS
and incubated with magnetic cell sorting (MACS) anti-
FITC magnetic microbeads (Miltenyi Biotec, Berisch-
Gladbach, Germany) for 30 minutes at 4°C. Cells were
washed twice and resuspended in PBS plus 0.1% BSA and
positively selected by the Vario MACS Column System
(Miltenyi). Positively selected cells were washed twice and
resuspended in PBS for intravenous injection.
Thoracic Duct Cannulation
Thoracic duct cannulation was used to obtain positively
selected host miHA-speciﬁc T cells, as previously described
[20,28]. BALB.B or CXBE mice (3 to 4 mice/group) were
irradiated (8.5 Gy) and injected intravenously 6 hours later
with CD4+-T cell–enriched or unseparated T cells (7  106
cells in 0.25 mL PBS) from naive or host-presensitized B6
mice and were cannulated 5 days later. Briefly, mice were
anesthetized by an IP injection of avertin (1:50 dilution in
PBS of a stock solution of 10 g tribromoethanol in 10 mL
tert-amyl alcohol; Aldrich Chemical, Milwaukee, WI), an
intravenous saline line inserted in the tail, and a cannula
(PE-50 intramedic tubing; Clay Adams, Parsipanny, NJ)
surgically implanted into the thoracic duct. TDL were col-
lected over a 20-hour period, and cells were pooled from at
least 3 mice per group.
Preparation of RNA and Complementary DNA
CD4+ T cells were prepared from TDL by panning the
cell suspension on GK1.5 (1:20 dilution of ascites fluid in
PBS plus 0.1% BSA) MoAb-coated plastic petri dishes for
1 hour at 4°C. Nonadherent cells were removed by gentle
washes with PBS. This procedure yielded an enriched popu-
lation of >96% CD4+ T cells. Total cellular RNA was pre-
pared from 106 to 107 puriﬁed CD4+ T cells by homogenizing
in 1 mL Ultraspec (Biotecx Laboratories, Houston, TX), sep-
arating cellular DNA and protein by the addition of a 1:5 vol-
ume of chloroform, vortexing for 5 seconds, and centrifuging
at 12,500 rpm for 15 minutes. The aqueous phase was trans-
ferred to a clean Eppendorf tube, and RNA was precipitated at
4°C by adding an equal volume of isopropanol and centrifug-
ing at 12,500 rpm for 15 minutes. The pellet was washed with
75% ethanol in diethylpyrocarbonate (DEPC)-treated water
and centrifuged again, and the RNA pellet was resuspended
in 25 mL DEPC water, heated to 55-65°C for 10 minutes,
and stored at –20°C. Recovery of RNA was determined by
spectrophotometry. The poly(A)+ portion of the total RNA
was converted into complementary DNA (cDNA) using
oligo(dT) as a primer for reverse transcription. Total RNA
(2 µg) in a volume of 9.5 µL was heated to 70-80°C, cen-
trifuged for a few seconds, and placed on ice. Master mix
(17.5 µL), containing 1 µL RNasin (40 U/µL), 6 µL of 5
Moloney murine leukemia virus (M-MLV) reverse transcrip-
tase reaction buffer, 3 L oligo(dT) primer (20 mmol/L),
1.5 µL dNTPS dA, -G, -C, -T (25 mmol/L each), and 3 L
M-MLV reverse transcriptase (300 U/L), was incubated at
37°C for 1.5 hours to synthesize cDNA. All reagents were
purchased from Promega (Madison, WI). The reaction mix-
ture was heated to 95°C for 3 minutes, and the cDNA was
stored at –20°C. PCR was performed using murine -actin
primers to establish the quality of the cDNA.
PCR Amplification of cDNA and CDR3-Size
Spectratyping
PCR was performed using a labeled constant primer
(Cb) and a V primer specific for each V family to be
analyzed. Cb was labeled using polynucleotide kinase
(Promega) and [32P]ATP (Dupont-NEN, Boston, MA). All
the primers used have been previously described [21,29].
Five microliters of 10 Taq polymerase buffer B (Promega)
was added to 5 L cDNA plus 2 L MgCl2 (25 mmol/L),
4 L dNTPS dA, -G, -C, -T (25 mmol/L each), 2.5 L V
sense primer (20 µmol/L), 4 L Cb-labeled antisense
primer (12 µmol/L), 28 L DEPC water, and 1 L Taq poly-
merase (2 to 5 U/L; Promega). Thirty-ﬁve cycles of ampliﬁ-
cation were carried out. On completion of PCR, 50 L of 2
loading buffer containing 95% formamide, 20 mmol/L
EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol
FF was added to each reaction. PCR reactions were either
stored at –20°C or electrophoresed. Each reaction tube was
heated to 70°C for 3 minutes, and 6 L of each was applied
to a prewarmed 6% acrylamide sequencing gel, as previously
described [21-23]. The gels were run at 55 mA for 1.5 hours
to maximize band resolution. Sequencing gels were dried, and
autoradiography was generally performed for 15 hours at
room temperature without intensifying screens.
Quantitation of CDR3-Size Usage
Densitometric scanning of autoradiographs was per-
formed on a Personal Densitometer SI using ImageQuant
software (Molecular Dynamics, Sunnyvale, CA). For each
V family, spectratype analysis was repeated 3 times for nor-
mal B6 control CD4+ splenic T cells and 2 times for the
experimental groups. The area under the corresponding
peaks was averaged for each V histogram. A band was con-
sidered to be skewed if the mean area under the peak was
greater than the mean plus 3 the standard deviation of the
corresponding normal control peak.
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Immunohistochemistry
Immunohistochemistry was performed as previously
described [30]. Brieﬂy, tongues and thymuses were removed
and cryopreserved by embedding in O.C.T. freezing com-
pound (Miles Laboratories, Elkhart, IN), snap-frozen in liq-
uid nitrogen, and stored at –80°C. Serial cryostat sections
were collected on glass slides coated with 3-aminopropyltri-
ethoxysilane, air dried, and ﬁxed in acetone for 5 minutes at
–20°C. Inﬁltrating lymphocyte populations were analyzed by
either of 2 immunohistochemistry methods. The first
approach involved a 20-minute room temperature prelimi-
nary blocking step with normal rabbit serum (diluted 1:10).
After excess serum was tapped off, sections were incubated
for 1 hour at room temperature with a panel of puriﬁed rat
anti-mouse MoAbs, which had been diluted in PBS plus
0.1% BSA and 0.1% NaN3, and directed to either CD4,
CD8 (1:400 dilution), , CD3 (1:200 dilution), or V6, -7,
-10, -11, and -14 (all at 1:50 dilution). In addition, sections
were stained with anti-CD31 (PeCAM; 1:400 dilution), an
adhesion protein expressed on the endothelial cell surface as
a positive control for the staining method. Afﬁnity-puriﬁed
biotinylated rabbit anti-rat polyclonal antibody (1:200 dilu-
tion) was then layered on the section for 30 minutes at room
temperature, followed by a PBS wash and addition of pre-
formed Vectastain Elite avidin-biotin-peroxidase (Vector
Labs, Burlingame, CA). Sections were developed for 3 min-
utes at room temperature with 3,3-diaminobenzidine
tetrahydrochloride. Alternatively, some sections were stained
with biotinylated mouse anti-mouse MoAbs directed to V5,
-8, -9, and -13 (all at 1:600 dilution), followed by ampliﬁca-
tion and development of this signal using the Renaissance
TSA-Indirect Kit (Dupont-NEN). The ﬁnal color-forming
substrate was diaminobenzidine tetrahydrochloride, applied for
no longer than 3 minutes at room temperature. After a brief
rinse in distilled water, sections were counterstained with
Mayer’s hematoxylin and then dehydrated and coverslipped.
RESULTS
General Approach
B6 T cells (7  106) were intravenously injected into
irradiated (9 Gy) BALB.B and CXBE mice for induction of
GVHD. Donor mice were presensitized to the appropriate
recipient type by primary and secondary IP injection of
1.5  107 host-type splenocytes. The recipients underwent
thoracic duct cannulation on day 5, and TDL was collected
over a 20-hour period and pooled from 3 to 4 mice per
group. The positively-selected TDL was >95% CD3+ and
consisted of 55% to 67% CD4+ and 33% to 45% CD8+
T cells. A signiﬁcant percentage (20% to 25%) of the TDL
cells were blast-like in size, in contrast to the low number of
blast-like cells found in control TDL collected from B6
mice who received transplants of T cells (1.5  107) from
syngeneic-presensitized B6 mice.
Induction of GVHD by B6 → BALB.B TDL T Cells
B6 CD4+ T cells (1.2  107) from positively selected
B6 → BALB.B TDL were transplanted along with 2  106
ATBM into a fresh set of lethally irradiated (9 Gy) BALB.B
recipients to demonstrate their GVHD-inducing potential.
Beginning on day 15, the recipients of CD4+ TDL cells
exhibited increasing clinical symptoms of GVHD, including
diarrhea, rufﬂed fur, and weight loss (reaching as much as
28% loss of initial body weight [Figure 1C]), compared with
control ATBM mice. Histological staining of lingual tissue
at day 50 indicated signiﬁcant lymphocytic inﬁltration in the
BALB.B recipients of B6 CD4+ TDL cells, indicative of
GVHD (Figure 1B), compared with mice injected with
ATBM cells only (Figure 1A). Mice receiving naive B6
CD4+ T cells did not express overt symptoms of GVHD
during the experimental period, consistent with previous
observations at similar donor dosage levels [17].
CD4+ TCR V Usage From TDL
PCR-based CDR3-size spectratyping was used to deter-
mine the precise nature of the V family involvement of naive
donor CD4+ T cells in the B6 → BALB.B and B6 → CXBE
TDL populations, as a reﬂection of their GVHD responses.
These experimental spectratypes for each V family were
compared with the distributions observed from normal B6
splenic CD4+ T cells, all of which followed an expected ran-
dom Gaussian distribution. It should be noted that in prelimi-
nary experiments, CD4+ TDL cells from B6 syngeneic control
recipients yielded spectratypes that displayed the same Gauss-
ian distribution as normal splenic CD4+ T cells (data not
shown) but were not used for the more extensive studies
described herein because of the technical difﬁculty in obtain-
ing enough of these cells for each experiment. Several experi-
mental V families retained Gaussian distributions, which
suggested their noninvolvement in the anti-miHA GVHD
response. As an example of this lack of detectable activity in a
given V family, spectratype analysis of V5 PCR products
generated from puriﬁed B6 naive splenic CD4+ T cells, B6 →
CXBE, and B6 → BALB.B CD4+ TDL RNA all exhibited
similar Gaussian distribution (Figure 2).
On the other hand, the V family spectratype patterns
from several experimental TDL samples exhibited specific
skewing of particular CDR3-size bands and therefore the
loss of a Gaussian distribution. For example, the analysis of
V14 PCR products generated from both B6 → CXBE and
B6 → BALB.B CD4+ TDL exhibited significant increased
intensity of band no. 1 relative to the distribution in the B6
control sample (Figure 3). These skewings were quantiﬁable
by comparing the percentage of the total areas under the
band curves, and denoted that positive increases in individual
bands were those with statistical signiﬁcance at P = .05 by the
Student t test. In a similar manner, the CDR3-size spec-
tratypes for all 18 V families expressed in B6 mice (V1-16,
18, and 20) were examined for skewed band distributions in
the positively selected B6 → CXBE and B6 → BALB.B
CD4+ TDL samples. The combined results (summarized in
Table 1) indicated overlapping biased CDR3 expansions in
the V4, 6 to 10, and 12 to 14 families of the 2 TDL popula-
tions. In each of these cases, the same CDR3-size band was
enhanced between the 2 strain combinations, and only a sin-
gle band per V family was involved. Another example of
this parallel distribution is observed in the spectratype for
V8 (Figure 4), where band no. 1 is skewed in both the B6
→ CXBE and B6 → BALB.B TDL populations.
Notably, only the B6 → BALB.B TDL exhibited biased
CDR3 usage in the V2 family, with skewing of band no. 5,
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and in the V11 family with skewing of band nos. 2 and 4
(Figure 5). In addition, the B6 → CXBE strain combination
exhibited unique skewing of band no. 3 in the V16 family
(Figure 6) and band no. 5 in the V18 family. Overall, the
spectratype results still suggested a limited oligoclonal CD4+
T-cell anti-miHA response in the 2 strain combinations,
conﬁrming previous phenotypic observations of V expan-
sions [20], but the approach was clearly more sensitive in
detecting the full scope of the in vivo response.
V Family Representation at the Site of 
GVHD-Related Epithelial Tissue Injury
Epidermal injury is a prominent histological diagnostic
feature of acute GVHD. Therefore, an in situ analysis of
CD4+ T-cell V use in sample target tissue was undertaken to
conﬁrm involvement in GVHD pathogenesis of V popula-
tions expressing CDR3 bias in the spectratype analyses.
Lethally irradiated (9 Gy) BALB.B mice were transplanted
with 2  106 B6 ATBM, alone or together with 2  107 naive
B6 CD4+ T cells. Within 15 days, the mice that received
CD4+ T cells began to exhibit clinical symptoms of GVHD,
including ruffled fur and diarrhea, compared with control
ATBM mice. At 30 days posttransplantation, the mice were
killed and their tongues were processed for immunohisto-
chemical analysis, as described in Materials and Methods.
Experimental murine and canine studies have indicated
that stem cells along the suprabasal epithelial rete ridges in
both skin and tongue are apparently targeted by effector cells
during acute GVHD [31,32]. Consequently, lingual epithe-
lium serves as an excellent representative site of GVHD-
induced pathology and can be readily used to characterize
infiltrating T cells participating in the antihost miHA
response. Serial sections of the lingual epithelium were
appropriately stained with MoAbs speciﬁc for CD3, CD4,
CD8, , and murine V families (V5-11, -13, and -14).
Increased cellular inﬁltration of CD3+ cells was observed in
the lingual epithelium of the mice that received naive B6
CD4+ T cells (Figures 7A and 7E), in comparison with few
detectable CD3+ cells in control mice that received ATBM
alone (not shown). All of these inﬁltrating CD3+ cells were
determined to be CD4+CD8––. The relative distribution of
the V families in the tissue (summarized in Table 2) sup-
ported the results obtained in the spectratype analysis. CD3+
T cells expressing V6, -7, -8, -9, and -13 were found to be
Figure 1. Graft-versus-host disease potential of B6 → BALB.B CD4+ thoracic duct lymphocyte (TDL) cells. BALB.B mice were lethally irradiated
(8.5 Gy) and injected intravenously with 2  106 anti-T-cell–depleted bone marrow (ATBM), alone or in a mixture with either 1.2  107 naive B6
CD4+ T cells (T) or positively selected B6 → BALB.B CD4+ TDL cells. Conventional histology of lingual epithelium from a BALB.B recipient 50
days after transplantation of ATBM alone (A) or with B6 → BALB.B CD4+ TDL cells (B). Note in B the population of inﬁltrating lymphocytes
along the damaged lingual squamous mucosal/submucosal interface. C, At each time indicated, the mean body weight for each recipient group (n =
5) was calculated and normalized as a percentage of the initial starting weight. SE for all groups was ≤5% of the mean values. 
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overrepresented (>2.0-fold the representation in a normal B6
CD4+ TDL population) to varying degrees in the tissue inﬁl-
trates. On the other hand, CD3+ T cells expressing V5
(Figure 7F and Table 2), which did not exhibit any CDR3-
size skewing, and V10, -11, and -14, which had shown evi-
dence of skewing, were either not increased or had only
marginal increases above normal levels at the site of tissue
injury (Table 2). V8 T cells were very dominant in the
infiltrate by absolute number, representing 36.5% of all
CD3+ T cells (Figure 7B and Table 2), exceeding their nor-
mal TDL constituency (7.8%) by 4.7-fold. Furthermore,
closer examination of the lingual epithelium revealed that
V8 infiltrating T cells were participating in a satellitosis
reaction pattern around target cells, characteristic of
GVHD lesions (Figures 7C and D). In addition to that in
the V8 family, the largest increase in expansion was in the
V9 family, with a 9.8-fold increase over their normal pres-
ence (0.6%) in the TDL population (Table 2).
GVHD Potential of Selected V Families
Magnetic cell sorting was used to positively select the
skewed V families to test their ability to potentiate lethal
GVHD in the B6 → BALB.B strain combination. Lethally
irradiated (9 Gy) BALB.B mice were transplanted with 2  106
B6 ATBM, alone or together with 1.7  107 unsorted host-
presensitized B6 CD4+ T cells, 9.8  106 selected host-presen-
sitized B6 skewed V+CD4+ T cells, or 7.1  106 selected host-
presensitized B6 V-depleted CD4+ T cells (the cell dosages of
the selected groups were adjusted to the original composition
of the unsorted population). The results indicated that both the
Figure 2. CDR3-size spectratype analysis of the V5 family. Poly-
merase chain reaction products were generated from the RNA of B6
naive splenic CD4+ T cells and host-presensitized B6 → CXBE and B6
→ BALB.B CD4+ thoracic duct lymphocyte cells. The spectratype
analysis was performed as described in Materials and Methods, and
densitometric scanning generated histograms that compared the rela-
tive intensities (optical density [OD]) of the bands in the 3 groups.
Figure 3. CDR3-size spectratype analysis of the V14 family. Densit-
ometric scanning of the spectratypes from the V14 RNA polymerase
chain reaction products of B6 naive splenic CD4+ T cells and host-
presensitized B6 → CXBE and B6 → BALB.B CD4+ thoracic duct
lymphocyte cells. Arrows indicate skewed bands within the spectratypes
relative to the B6 control sample. OD indicates optical density.
Table 1. Summary of T-Cell Receptor V Use of CD4+ Thoracic Duct
Lymphocyte Cells From CXBE and BALB.B Recipients Transplanted With
Host-Presensitized B6 T Cells and Analyzed by CDR3-Size Spectratyping*
CXBE BALB.B
Skewed Band No. Skewed Band No.
V Pattern Skewed† Pattern Skewed
1 – –
2 – + 5
3 – –
4 +‡ 4 + 4
51/2 – –
6 + 1 + 1
7 + 1 + 1
81/2/3 + 1 + 1
9 + 1 + 1
10 + 1 + 1
11 – + 2,4
12 + 4 + 4
13 + 1 + 1
14 + 1 + 1
15 – –
16 + 3 –
18 + 5 –
20 – –
*Irradiated CXBE and BALB.B mice were injected with 7  106
host-presensitized B6 donor T cells and cannulated 5 days later. Tho-
racic duct lymphocyte cells were collected from 3 to 4 mice per group,
CD4+ T cells were isolated, and CDR3-size spectratype analysis was
performed. Results were consistent from 2 separate experiments involv-
ing different sets of mice. 
†Spectratype bands were assigned numbers from 1 to 5, from
higher to lower molecular weight within each V family
‡+ indicates that the area under the band curve was significantly
increased over the same band in the normal B6 splenic CD4+ T-cell
distribution, with P = .05 by Student t test.
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unsorted CD4+ T cells and the positively selected skewed
V+CD4+ T cells were capable of inducing lethal GVHD in all
of the recipients within 110 days (mean survival time [MST] of
80 and 40 days, respectively; Figure 8). In comparison, the
mice transplanted with the select V-depleted CD4+ T cells all
survived with minimal symptoms of GVHD.
DISCUSSION
The capacity for CD4+ T cells to mediate GVHD
directed to class II–restricted miHA has been well estab-
lished in murine model systems [16-19,33,34]. CD4+
T cells can participate in development of disease at multi-
ple levels, providing inflammatory cytokines for support
of other cell mediators, particularly for the generation of
CD8+ cytotoxic T lymphocytes (CTL), but they may also
act directly against host target tissue through their own
cytolytic mechanisms. In some strain combinations, eg,
B6 → BALB.B [17], CD4+ T cells can cause lethal GVHD
by themselves, yet the basis for these aggressive responses is
not well understood. TCR V repertoire analysis is an
effective means to gain insight into the nature of these
complex CD4+ T-cell responses [20,35,36].
TCR V repertoire analysis was performed on posi-
tively selected TDL collected from host-presensitized B6 →
BALB.B and B6 → CXBE mice receiving transplants at an
early stage in the development of GVHD. TDL is an excel-
lent source for monitoring T-cell responses, because
recently activated T cells enter the thoracic duct after ini-
tially encountering miHA in the lymphoid system and sub-
sequent to expansion. It is particularly important that the
cells can be retrieved with high viability (≥99%) and with
very little tampering, in contrast to the standard retrieval
methods of cells from the spleen or LN tissues, and that
they can contain signiﬁcant levels of blast-like T cells [37].
Figure 4. CDR3-size spectratype analysis of the V8 family. Spec-
tratype analysis of V8 RNA polymerase chain reaction products gen-
erated from B6 naive splenic CD4+ T cells and host-presensitized B6
→ CXBE and B6 → BALB.B CD4+ thoracic duct lymphocyte cells.
Arrows indicate skewed bands within the spectratypes. OD indicates
optical density.
Figure 5. CDR3-size spectratype analysis of the V11 family. Spec-
tratype analysis of V11 RNA polymerase chain reaction products
generated from B6 naive splenic CD4+ T cells and host-presensitized
B6 → CXBE and B6 → BALB.B CD4+ thoracic duct lymphocyte cells.
Arrows indicate skewed bands within the anti-BALB.B spectratype.
OD indicates optical density.
Figure 6. CDR3-size spectratype analysis of the V16 family. Spec-
tratype analysis of V16 RNA polymerase chain reaction products gen-
erated from B6 naive splenic CD4+ T cells and host-presensitized
B6 → CXBE and B6 → BALB.B CD4+ thoracic duct lymphocyte cells.
The arrow indicates a skewed band within the anti-CXBE spec-
tratype. The area of this band is 37.9% (SD ± 1.06), 45.9%, and 36.9%
for the B6, anti-CXBE, and anti-BALB.B, respectively. OD indicates
optical density.
CD4+ TCR V Repertoire in GVHD
9B B & M T
Phenotypic analysis of the TDL repertoire using
MoAbs was previously limited by the lack of reagents for all
murine V families, the lack of sensitivity, and the inability
to ultimately characterize unique TCR clonotypes. In con-
trast, T-cell repertoire analysis based on the size hetero-
geneity of the CDR3 region has become a powerful tool for
the study of immune responses [21,24,38,39]. Using CDR3-
size spectratyping analysis, we have generated a more com-
plete picture of the in vivo donor CD4+ T-cell response to
host miHA. In addition to conﬁrming V6, -7, -8, and -9
responses previously detected by MoAbs in BALB.B recipi-
ents, spectratyping established the additional involvement of
V4, -10, -12, -13, and -14 families that were all common to
the CXBE recipients. Of most interest, CDR3-size skewings
unique to the BALB.B recipients were found in the V2 and
V11 families, and the TCR specificities and functional
capabilities of the T cells that these clonal or oligoclonal
expansions represent may ultimately provide clues as to why
these particular GVHD responses result in fatality.
There are several possible factors responsible for the
level of heterogeneity of the anti-miHA response observed
by CDR3-size spectratyping analysis of the early GVHD
TDL. GVHD may be mediated by a heterogeneous popu-
lation of alloreactive CD4+ T cells that recognize either a
limited number of or several different host miHA pre-
sented by MHC class II+ APCs. In other antigenic systems,
it has been found that T-cell clones specific for the same
epitope have used highly diverse TCR sequences
[29,40,41]. In regard to responses to BALB.B miHA,
Wettstein [42] reported a minimum of 6 different class
II–restricted miHA encoded by independently segregating
genes, as defined by proliferation responses to stimulator
cells from a panel of 11 CXB RI strains. It is therefore pos-
sible that multiple TCRs can recognize each of these
BALB.B epitopes, because T-cell recognition involves the
interaction of both V and V chains [43]. Diverse V
chains could also associate with a different V chain to
recognize the same epitope, a phenomenon that has been
Figure 7. Immunohistochemistry of lingual epithelium from lethally irradiated (8.5 Gy) BALB.B recipients, 30 days after transplantation with 2 
106 anti-T-cell–depleted bone marrow and 2  107 naive B6 CD4+ T cells. A, Characteristic inﬁltrate of CD3+ cells within the lowest layers of the lin-
gual squamous mucosa. B, An adjacent section stained for V8. C, Higher magniﬁcation of clustered CD3+ T cells within the lingual epithelium (e).
D, *In a section adjacent to C, the V8+ T-cell component of this aggregate is distributed at the periphery of larger, nonstaining dyskeratotic target
cells. In contrast to the V8+ presence, CD3+ positive cells (E) only rarely indicated V5 family immunoreactivity (F). (A, B, E, F: original magniﬁca-
tion, 200; C and D: original magniﬁcation, 1000).
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observed in the diversity of CD4+ T-cell responses to
influenza antigenic determinants [44].
In a previous study of CXB RI interstrain lethal GVHD
responses, it was determined that there was a minimal
involvement of 2 distinct miHAs in the B6 → BALB.B
GVHD response [45]. At least 1 class II–restricted miHA
(GVH-1) appeared to be shared between the BALB.B and
CXBE strains and likely provided the CD4+ T-cell response
necessary for the development of CD8+ T cell–mediated
pathogenesis. In addition, at least a second miHA (GVH-2)
was uniquely expressed by the BALB.B strain and was asso-
ciated with the generation of the CD4+ T–cell pathogenesis
[17,45]. The biased CDR3-size skewing of V4, -6, -7, -8,
-9, -10, -12, -13, and -14 families in both the BALB.B and
CXBE recipients may represent a response to the former set
of common miHA shared by BALB.B and CXBE mice, ie,
GVH-1. Although the same CDR3-size bands were skewed
in each corresponding V family, final identity of these
speciﬁcities will depend on sequence analyses of the CDR3
segments involved in each response.
To account for the lethal CD4+ T–cell response in the
B6 → BALB.B strain combination, biased CDR3 usage of
V2 and -11 families, not present in the spectratype of the
CXBE recipients, would seemingly represent responses to
unique BALB.B miHA, ie, GVH-2. CXBE mice simply may
not express the BALB.B allele at the locus encoding for the
miHA in question. Alternatively, the absence of the response
could reﬂect the lack of presentation of this miHA because of
ineffective antigen processing, in a manner similar to that
observed for the response to hen egg lysozyme peptide 46-61
by C3H.SW and B6 mice [46]. In either case, the V2 and
V11 reactive T cells may define unique specificities for
miHA that are effectively expressed only in the BALB.B
hosts. It could be hypothesized that the T cells responding to
these unique BALB.B miHA may be induced to favor pro-
duction of particular inﬂammatory cytokines or the capacity
to mediate direct cytolytic activity (eg, Fas ligand or per-
forin-granule capabilities) induced by the particular miHA
interactions. Such selective activation has been observed in
altered ligand systems with CD8+ T cells [47-49]. There are
also data that suggests that cytolytic and cytokine functions
can be separately induced by antigen in CD4+ T cells [50].
Alternatively, or in addition to that scenario, the V2 and
11 CD4+ T–cell responses may be directed to miHAs that
are differentially expressed in particularly sensitive target tis-
sue sites [51,52] and may thus significantly contribute to
GVHD pathogenesis and subsequent fatality.
It is estimated that a minimum of 29 miHA locus differ-
ences exist between the B6 and BALB/c inbred mouse
strains [53], yet only a few immunodominant miHAs appear
Table 2. Immunohistochemical Analysis of Inﬁltrating T cells in Lingual Epithelium During B6 → BALB.B Graft-Versus-Host Disease*
% V in Fold increase in
V Family CD3+ Cells/Linear, mm† V+ Cells/Linear, mm % of CD3+ Cells V+ CD4+ B6 TDL‡ V Family Representation§
51/2 33.2 ± 5.4 0.5 ± 0.4 1.6 1.3 1.2
6 32.1 ± 2.3 3.9 ± 0.8 11.8 4.0 2.9
7 42.1 ± 1.8 0.9 ± 0.3 2.7 0.8 3.4
81/2/3 27.8 ± 1.2 10.1 ± 0.9 36.5 7.8 4.7
9 30.0 ± 3.8 1.7 ± 0.5 5.9 0.6 9.8
10 43.5 ± 3.2 1.3 ± 0.6 2.9 2.4 1.2
11 38.4 ± 5.8 2.0 ± 0.4 5.3 2.8 1.9
13 41.5 ± 3.6 1.0 ± 0.3 2.4 0.8 3.0
14 34.6 ± 4.8 0.8 ± 0.2 2.3 4.7 0.5
*Irradiated BALB.B mice were injected with 2  107 naive B6 CD4+ T cells and 2  106 anti-T-cell–depleted bone marrow. At day 30, tongues
were harvested for immunohistochemical analysis of tissues. CD3+ cells were CD4+CD8–– by staining, as described in “Materials and Methods.”
TDL indicates thoracic duct lymphocyte.
†Cell/linear mm measurements were based on the total number of stained cells counted per section divided by the perimeter in mm of each
section. Cell numbers were expressed as averages from 4 separately stained sections of tissue taken 2 each from 2 different mice ± SE. Anti-
T-cell–depleted bone marrow controls had an average of 2.4 CD3+ cells per linear mm.
‡Percentages of V expression as previously determined by phenotypic analysis of normal B6 TDL [20].
§Fold expansion is deﬁned as the percentage of CD3 V+ cells in the tissue divided by the percentage V expression in normal TDL.
Figure 8. Graft-versus-host disease potential of B6 CD4+ T cells from
select V families (V2, -4, -6 to -14) transplanted into BALB.B mice.
BALB.B mice were lethally irradiated (8.5 Gy) and injected intravenously
with 2  106 anti-T-cell–depleted bone marrow (ATBM), alone or in a
mixture with either 1.7  107 unseparated B6 CD4+ T cells, 9.8  106
select V+CD4+ T cells, or 7.1  106 select V-depleted CD4+ T cells.
All donor CD4+ T cells were from B6 mice that had been presensitized by
intraperitoneal injection of BALB.B splenocytes 3 weeks before transplan-
tation (n = 5 to 6 mice for all groups). T indicates T cells.
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to be recognized in vivo by allogeneic T cells responsible for
skin graft rejection [54]. An immunodominant hierarchy was
also found to operate for the generation of B6 anti-BALB.B
miHA-specific CTL in vitro [55]. Given that the CXBE
mouse strain contains a subset of the miHAs found in the
BALB.B mice, the unique skewing of the V16 and -18
families in the CXBE recipients could be evidence of
immunodominance between the BALB.B-speciﬁc (V2 and
-11) responses and subdominant responses (V16 and -18).
Immunodominance of miHAs may reflect more vigorous
T-cell responses to certain epitopes, on either a cellular or
population basis, that may downregulate weaker responses
to other miHAs via cytokine production. Along these lines,
immunodominance itself may be defined not solely by
attributes of the speciﬁc TCR for miHAs, but rather by the
heterogeneity of the responding T-cell population. The
more heterogeneous the T-cell response, the larger the size
of the starting pool and the more dominant the response.
Alternatively, the stability of the interaction of the speciﬁc
TCR for miHA/self-MHC may also be an important factor
of miHA immunodominance. Evidence to support both of
these hypotheses has recently been reported for responses to
bacterial antigens [56] and persistent Epstein-Barr virus
infections [57]. Each of these potential mechanisms or com-
binations thereof could account for the phenomenon of
competitive immunodominance in the response to miHA.
The opposite side of the argument is that these V
responses are not at all related to lethal GVHD but that the
overall level of responses in the BALB.B recipients are
merely greater than that in the CXBE mice. This greater
response could be at the level of clonal frequencies of the
speciﬁcities involved or perhaps at the local level of inﬂam-
matory cytokines produced. However, other factors may
also influence the development of GVHD severity, eg,
genetic differences between the 2 strains in tissue expression
of adhesion molecules important for allowing T-cell inﬁltra-
tion [58]. Many of these possibilities can be clariﬁed as we
continue to investigate the components of these responses
and characterize their roles in pathological development.
Histological analysis of BALB.B recipient lingual
epithelium revealed a large number of infiltrating CD3+
T cells concentrated at the suprabasal epithelial rete region.
These results parallel those of previous work that showed
that, during a GVH response, localization of epithelial apo-
ptosis, lymphoid inﬁltration, and dyskeratosis is restricted to
this area [59]. Moreover, for the V families that could be
examined by immunohistochemistry, the results indicated
that many of the V families expressing CDR3-size expan-
sion as detected by spectratyping were overrepresented at
the site of GVHD lesions, compared with their distribution
in normal TDL. Interestingly, V14, which also was found
to be skewed by spectratyping, was actually underrepre-
sented at the tissue site. Hypothetically, this could again be
attributable to lack of appropriate miHA expression in the
tissue or problems in T-cell migration.
Immunohistochemical staining clearly demonstrated
that V9 was the most overrepresented V family within
the epithelial tissue infiltrate (based on the frequency of
V9 using cells among the normal TDL population).
Although this ﬁnding could suggest that a large prolifera-
tive response in the periphery had preceded target tissue
infiltration of V9 cells, their overall number within the
targeted epithelium was relatively low compared with that
of V8 cells. Regarding the high V8 cell presence, even
though these cells are normally represented in a high per-
centage of peripheral CD4+ T cells, their approximately
5-fold increase at the tissue site also strongly suggests their
involvement in GVHD pathogenesis. This perspective is
underscored by the number of V8 cells found clustered
around dying keratinocytes. Such satellitosis reaction pat-
terns characterize, in part, GVHD skin lesions [60] and
strongly support a direct role for this V family in respond-
ing to speciﬁc miHAs presented by host keratinocytes. Fur-
thermore, it is likely that cells expressing V6, -7, and -9
are also involved in similar lymphocyte-keratinocyte inter-
actions because of their overrepresentation in the epithelial
tissue. However, because of their lower absolute number in
the inﬁltrate, satellitosis reaction patterns were less evident
than with V8 cells.
Of most signiﬁcance was the increased survival observed
in the BALB.B mice that received transplants of CD4+
T cells depleted of the skewed V families (Figure 8). This
targeted depletion of the GVH-reactive T cells from the
donor inoculum could allow the residual T cells to counter-
act infection, promote engraftment, and potentially mount
GVL responses in recipient mice. The shorter MST
(40 days) observed in the mice that received the positively
selected skewed V families, compared with that in mice that
received unsorted CD4+ T cells (MST 80 days), could reﬂect
potential increased activation of these V families by the
selecting antibodies. However, because the mice that
received unsorted CD4+ T cells exhibited GVHD pathology,
and expansion of several skewed V+ families does correlate
with target organ injury in lingual epithelial tissue (Figure 7
and Table 2), the observed lethality in these recipients was
likely to have been induced by speciﬁc GVHD reactivity.
The characterization of the CD4+ T–cell repertoire in
the response to multiple miHAs during the development of
GVHD in this murine model will help us to understand the
scope and dynamics of this complex immunopathological
process and will ultimately help to determine the nature of
the miHAs responsible for its induction.
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